I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Extraskeletal myxoid chondrosarcoma (EMC) is a malignant soft tissue tumor characterized by a multinodular architecture, abundant myxoid matrix, and malignant chondroblast-like cells arranged in cords, clusters, or delicate networks. It was first described by Enzinger and Shiraki in 1972 as a distinct tumor type.\[[@ref1]\] EMC has been classified by the WHO as a tumor of uncertain differentiation in its classification of tumors of soft tissues and bones.\[[@ref2]\] Chondrosarcomas are the third most common primary malignancy of bone after myeloma and osteosarcoma that produces cartilaginous matrix.\[[@ref3]\] Myxoid chondrosarcoma is an intermediate subtype, which is found in either bones or soft tissues. EMC is a separate entity from chondrosarcomas of bones commonly found in the soft tissues of the lower extremities (80%) and in the trunk (20%). To the best of our knowledge, 42 EMC cases of the head and neck region have been reported in literature, including the present report. Of these EMCs, only one previous case arose from the parotid gland region. The purpose of this paper was to describe an EMC reported at an unusual site in the parotid gland. In addition, the literature review was briefly discussed with special reference to the possible clinicopathological features and the treatment of EMC.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

A 56-year-old female was admitted in the Department of Oral Maxillofacial Head and Neck Oncology Surgery with a history of painless mass of the left posterior region of the parotid gland. The swelling was slowly progressive over a period of 2 months and there were no associated systemic symptoms. Physical examination revealed a parotid mass 1.5 cm × 2 cm × 2 cm in size, firm in consistency, and with no palpable cervical lymph nodes. The preoperative computed tomography (CT) scan depicted a 4.5 cm × 3.4 cm × 3.2 cm sized irregular lobular mass involving the deep lobe of the left parotid gland. Margins were clear, uneven texture, and the compression of the left internal jugular vein with the forward displacement was observed. The cervical lymph nodes were not enlarged \[[Figure 1a](#F1){ref-type="fig"}\]. The coronal CT demonstrated a soft tissue mass that extended up to the left temporal bone \[[Figure 1b](#F1){ref-type="fig"}\]. Parotid gland pleomorphism adenoma or facial nerve neurilemmoma was the clinical differential diagnosis. Following discussion and after obtaining consent from the patient, left partial parotidectomy with conservation of facial nerve was performed under general anesthesia. During the course of the surgery, the tumor was identified with an intact capsule and jugular vein, and the carotid artery was palpated \[Figure [2a](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"}\].

![CT Scan showed an irregular lobular mass on the left parotid gland involving deep lobe with clear boundary and showing compression of the left internal jugular vein without cervical lymph nodes enlargement (a), The coronal incidence demonstrating a heterogeneous soft-tissue mass extended upon to the left temporal bone, and the boundary was not a rough (b)](AMS-9-439-g001){#F1}

![View of intraoperative shows conservation of facial nerve (a) with excision of tumour (b) Palpated vessels (c)](AMS-9-439-g002){#F2}

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-3}
=================================================

A biopsy specimen was collected, fixed immediately in 4% buffered paraformaldehyde, and embedded in paraffin and then cut at a thickness of approximately 4 μm. The study was performed strictly in accordance with the guidelines set forth by the Review Board of the Ethics Committee in the Hospital of Stomatology, Wuhan University. Macroscopic pathology showed the tumor was grossly jelly like with a localized myxoid transparent appearance and irregular. In hematoxylin and eosin-stained section (×10), the tumor was highlighting nodular or lobulated growth pattern. The tumor cells were small with uniform size and shape, with a small hyperchromatic nucleus and a moderate amount of eosinophilic cytoplasm that was occasionally vacuolated. These cells were embedded in an abundant mucus-like matrix, with rare mitoses and cartilage differentiation. Alignment of the tumor cells in strands and cords separated by myxoid stroma was characteristic of EMC \[[Figure 3](#F3){ref-type="fig"}\].

![Histological features of the tumor showed cells embedded in a mucus-like matrix structure (×10), cells relatively small with uniform size and shape, alignment in strands and cords separated by large amount of myxoid stroma](AMS-9-439-g003){#F3}

In accordance to a pathology book on salivary glands,\[[@ref4]\] immunohistochemical studies were performed on paraffin sections of the parotid gland mass using antibodies against antigens. To evaluate the immunoreactivity, we assessed the staining areas of the markers. The numbers of stained cells were counted at an original magnification of ×200 in five random fields by two investigators. The images were then analyzed using the ImageJ version 1.48v. Immunocytochemical staining showing reactivity for marker S-100, vimentin, and Ki-67 was focally and weakly positive (\<5%) as well. The tumor cells did not react with antibodies to the keratin, calponin, desmin, P63, NSE, and Syn. Based on these findings, the diagnosis of EMC was rendered. After a follow-up period of 12 months, the postoperative course was uneventful, and as of the time of writing, no recurrence had appeared.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

EMCs are a group of rare malignancies of soft-tissue sarcomas whose ultrastructural and molecular features are distinct from that of myxoid chondrosarcoma. Clinical examination of EMC has no specific findings which separates it from other types of chondrosarcomas. Pain, tenderness, and detection of a palpable mass may characterize some cases.\[[@ref5]\] Tumors arising in specific sites can produce associated symptoms and large or superficial tumors may ulcerate the skin. EMC is low-grade malignant tumors with a predilection for males;\[[@ref6]\] as from 42 cases found in literature, males were affected in 59.52% (*n* = 25) and females in 35.71% (*n* = 15), and 4.86% (*n* = 2 cases) were unavailable \[[Table 1](#T1){ref-type="table"}\]. In addition, the age group ranging from 36 to 66 was the most affected (45.23%; *n* = 19) as for the present case. Imaging characteristics are nonspecific, most tumors appear lobulated, and highly myxoid tumors have a homogeneous high signal on T2-weighted magnetic resonance imaging image.\[[@ref5]\] Furthermore, as the tumor may undergo hemorrhagic and necrotic degeneration, signal characteristics on T1-weighted magnetic resonance images could be varied, ranging from low, intermediate, to high intensity compared to muscles. Calcification is usually absent as in this report and, if present, it is not prominent. Since its original description, EMC of the head and neck is a rare entity, occurring less than 3% of all soft-tissue sarcomas,\[[@ref2]\] including the nasal cavity, buccal mucosa, neck region, infratemporal fossa, sphenoidal sinus, base of the tongue, and the parotid gland \[[Table 1](#T1){ref-type="table"}\]. To date, there is only one previous report of EMC involving the parotid gland.

###### 

Epidemiological summary of extraskeletal myxoid chondrosarcoma of the head and neck reported in the literature

  Authors' names                        Publication years   NC        Age/sex      Location                   Treatment      Follow-up (months)   Recurrence/observation
  ------------------------------------- ------------------- --------- ------------ -------------------------- -------------- -------------------- ------------------------
  Present case                          \-                  1         56/male      Parotid gland              Surgery        12                   None/alive
  Ceylan *et al*.\[[@ref5]\]            2006                1         35/female    Nasal cavity               Surgery        9                    None/alive
  Ratnadeep and Abhishek\[[@ref7]\]     2011                1         61/male      Nasal cavity               Surgery        3                    Yes/alive
  Angiero\[[@ref8]\]                    2012                1         102/female   Buccal mucosa              Surgery        UA                   UA
  Oh *et al*.\[[@ref9]\]                2013                1         62/female    Neck                       Surgery        UA                   UA
  Antonescu *et al*.\[[@ref10]\]        1998                2         82/male      Neck                       Surgery        60                   Yes/died
  53/male                               Neck                Surgery   4            None/alive                                                     
  Navdeep *et al*.\[[@ref11]\]          2017                1         65/male      Neck                       Surgery        UA                   UA
  Zaki *et al*.\[[@ref12]\]             2015                1         65/male      Neck                       RT + CT        2                    None/alive
  Acero *et al*.\[[@ref13]\]            2003                1         22/female    Infratemporal fossa        Surg + RT      36                   None/alive
  Jérôme-Marson *et al*.\[[@ref14]\]    2003                2         67/male      Nasal cavity               RT             7                    UA
  71/female                             Sphenoid sinus      RT        4            UA                                                             
  Sotomayor *et al*.\[[@ref15]\]        2007                1         80/male      Base of the tongue         IB             14 days              Died
  Shao *et al*.\[[@ref16]\]             2016                1         56/male      Parotid gland              Surgery        12                   None/alive
  Jawad *et al*.\[[@ref17]\]            1991                1         45/male      Maxillary sinus            Surgery        18                   None/alive
  Drilon *et al*.\[[@ref18]\]           2008                1         UV           Head and neck              UA             UA                   UA
  Jung *et al*.\[[@ref19]\]             2011                1         69/female    Masticator Space           Surg + RT      3                    None/alive
  Romañach *et al*.\[[@ref20]\]         2017                1         13/male      Masticator space           Surg + RT      12                   Yes/died
  Englert *et al*.\[[@ref21]\]          1978                1         43/male      Mandibular metastasis      Palliative     UA                   UA
  Tsuneyoshi *et al*.\[[@ref22]\]       1981                2         16/male      Nasal cavity               Surgery        5                    Yes/died
  66/male                               Neck                Surgery   2            None/alive                                                     
  Charabi *et al*.\[[@ref23]\]          1989                1         34/female    Temporal bone              Surgery        18                   None/alive
  Liu-Shindo *et al*.\[[@ref24]\]       1989                1         51/female    Skin, over the mentum      Surg + RT      15                   None/alive
  Salcman *et al*.\[[@ref25]\]          1992                1         28/female    Intracranial               Surg + RT      22                   Yes/alive
  Sato *et al*.\[[@ref26]\]             1993                1         43/female    Intracranial               Surg, RT, CT   UA                   Yes/died
  Worley *et al*.\[[@ref27]\]           1999                1         42/male      External auditory meatus   Surgery        9                    None/Alive
  Oshiro *et al*.\[[@ref28]\]           2000                1         66/male      Neck, scapula              UA             12                   None/alive
  De Las Casas *et al*.\[[@ref29]\]     2000                1         44/male      Spheinodal sinus           Surg + RT      16                   None/alive
  Goh *et al*.\[[@ref30]\]              2001                2         65/male      Epidural                   UA             UA                   UA
  70/male                               Supraclavicular     UA        UA           UA                                                             
  Deik *et al*.\[[@ref31]\]             2009                1         94/male      Supraclavicular            UA             UA                   UA
  Bahri *et al*.\[[@ref32]\]            2002                1         67/female    Parapharyngeal space       Surg + RT      7                    None/alive
  González-Lois *et al*.\[[@ref33]\]    2002                1         17/female    Intracranial               Surg + RT      20                   Yes/alive
  Cummings *et al*.\[[@ref34]\]         2004                1         63/male      Jugular foramen            UV             UV                   UA
  Jörg *et al*.\[[@ref35]\]             2006                1         8/male       Maxilla                    Surgery        18                   None/alive
  Saint-Blancard *et al*.\[[@ref36]\]   2006                1         67/female    Neck                       Surgery        UA                   UA
  Nakazora *et al*.\[[@ref37]\]         2006                1         48/male      Clavicle                   Surgery        36                   None/alive
  Betz *et al*.\[[@ref38]\]             2007                1         88/UV        Nasal septum               Surgery        13                   Yes/alive
  Kim *et al*.\[[@ref39]\]              2007                1         10/male      Sinonasal cavity           Surg + RT      UA                   UA
  O'Brien *et al*.\[[@ref40]\]          2008                1         26/female    Cerebellopontine angle     Surg + RT      12                   None/A
  Willems *et al*.\[[@ref41]\]          2008                1         32/male      Neck                       UA             UA                   UA
  Kaplan *et al*.\[[@ref42]\]           2010                1         37/female    Maxillary sinus            Surg + RT      18                   None/alive

Surg=Surgery; UA=Unavailable; RT=Radiotherapy; CT=Chemotherapy; IB=Incisional biopsy; NC=Number of case

The pathogenesis of EMC remains controversial. Surgical or accidental trauma may be key factors, along with the inhalation of chemical carcinogens such as hydrocarbons.\[[@ref17]\] Our patient did not report any head and neck region trauma. Another theory suggested that these tumors arise from a primitive mesenchymal or a synovial intimal cell with a propensity for differentiation. EMC is lobulated or multinodular and varies from gray to tan in color with a gelatinous and mucoid consistency. The pathological characteristics of the surface of EMC are myxoid or jelly-like, with a localized myxoid-like transparent appearance; cysts, hemorrhage, or necrosis may be observed. Under a light microscope, EMC usually exhibits a nodular structure with abundant myxoid stroma.\[[@ref43]\] Histologically, it is characterized by a collection of round-to-spindle-shaped cells; arranged in cords, strands, and nests; and surrounded by a mucinous, hypovascular matrix. The cell nuclei demonstrate minimal to absent pleomorphism, hyperchromatic nuclei, and are surrounded by eosinophilic cytoplasm which is occasionally vacuolated.\[[@ref44]\] Even though EMC is now recognized as a distinct lesion from chondrosarcomas of the bones, the term EMC probably still a misnomer for this tumor and does not highlight its true chondrosarcomatous differentiation. Three distinct histologic patterns of EMC have been described in the literature such as solid type, the rhabdoid phenotype (a rare type) and the classical EMC as described in the present paper, which presents as a low grade tumor with loose matrix, fibrils and myxoid material.\[[@ref45]\] Compared to the solid tumor type, the latter usually has a large vesicular nucleus and increased mitotic activity. The classical EMC is the most common type that is less aggressive than chondrosarcomas of the bone.

The treatment of EMC is largely surgical excision as demonstrated in [Table 1](#T1){ref-type="table"}. Even with adequate surgical margins, however, the technical complexities related to this anatomical region, complete tumor resection often is not achieved, thus resulting in a poorer prognosis.\[[@ref13]\] Therefore, en bloc resection and the longitudinal follow-up are necessary. The present case was treated by superficial parotidectomy, and after postoperative follow-up of 12 months, no signs of recurrence had appeared unlike as reported in the case of Ratnadeep and Abhishek\[[@ref7]\] in which recurrence was detected three months after surgery. Even though the overall prognosis of EMC is difficult to estimate due to rarity of the tumor, one report demonstrated 5-year survival rate to be 82% and 65% survival rate at 10-year with 48% of local recurrence and 46% of metastases.\[[@ref18]\] There are prognostic variations depending on cellularity, cellular maturity, differentiation, and amount of myxoid matrix. Dedifferentiated EMC is assumed to be more aggressive.\[[@ref19]\] Some reports suggest that the tumor showing increased cellularity and atypia is more aggressive\[[@ref10][@ref44]\] and the presence of rhabdoid cells may be an adverse histologic variable.\[[@ref28]\] In addition, older patients with larger tumors, especially greater than 10 cm, have poorer prognosis. To date, the use of radiotherapy for EMC is controversial, and optimal chemotherapy regimen remains unclear determined. Some studies show that these tumors are resistant to radiotherapy, while others maintain that radiotherapy should be considered.\[[@ref28]\]

While hematoxylin-eosin staining remains the gold standard for salivary gland tumor diagnosis, immunohistochemistry (IHC) is more commonly being used to obtain better understanding of the morphogenesis of the disease and to enhance diagnostic accuracy.\[[@ref7]\] IHC marker panels can support and may be useful in refining the diagnosis of EMC. Vimentin is the only marker consistently expressed in EMC,\[[@ref5][@ref16][@ref43]\] while S-100 protein, synaptophysin, cytokeratin, and epithelial membrane antigen are focally expressed in a minority of tumors. In the present case, S-100 protein and vimentin had the highest expression. Reactivity with vimentin, S-100 protein, and EMA has also been reported.\[[@ref46]\] The analysis of IHC markers associated with the location of the lesion; cytology and radiology factors constitute systematic keywords for the diagnosis of EMC. Therefore, a meticulous academic exercise for analysis and interpretation of the findings is mandatory. In the recent study, Ki-67 index was remarkably higher in cellular variant (N30%) but 5%--10% in a classic EMC variety,\[[@ref16]\] which was similar to the present report. The low proliferative index as shown by Ki-67 (\<5%), i.e., low mitotic activity, appears to be associated with a good outcome.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

Although some reports have been published about EMC in the head and neck region, there is an extremely limited report in the parotid gland. EMC should remain in the differential diagnosis for a soft-tissue parotid gland mass. The histological and immunohistochemical features associated with clinical features are essential for the diagnosis of such lesions.
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